- Conditions
- Non-Small Cell Lung Cancer and Pleural Mesothelioma
- Interventions
- PTK787 and Pemetrexed with or without Cisplatin
- Drug
- Lead sponsor
- Nevada Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 7,390
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dementia of Alzheimer's Type
- Interventions
- Donepezil, Solifenacin
- Drug
- Lead sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Deerfield Beach, Florida • Miami, Florida • West Palm Beach, Florida + 1 more
- Conditions
- Dilated Cardiomyopathy
- Interventions
- Allogeneic Neonatal mesenchymal stromal cells (nMSCs)
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 4 Years to 40 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia
- Conditions
- Renal Impairment
- Interventions
- Brensocatib
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Tampa, Florida • San Antonio, Texas
- Conditions
- HCV Infection
- Interventions
- GS-9450, GS-9450 Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 5
- States / cities
- Anaheim, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more
- Conditions
- Hypertriglyceridemia, Severe Hypertriglyceridemia
- Interventions
- ION775
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 16
- States / cities
- Lincoln, California • Aurora, Colorado • Boca Raton, Florida + 13 more
- Conditions
- Multiple Myeloma
- Interventions
- Cohort 1: Carfilzomib 15 mg/m2, Cohort 2: Carfilzomib 20 mg/m2, Cohort 2b: Carfilzomib 20 mg/m2, Cohort 3b: Carfilzomib 27 mg/m2
- Drug
- Lead sponsor
- Corewell Health West
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Myelodysplastic Syndromes
- Interventions
- filgrastim, clofarabine, cytarabine, microarray analysis, biopsy
- Biological · Drug · Genetic + 1 more
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 120 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Obesity, Overweight, Weight Loss, Diet Habit
- Interventions
- Weight Management Intervention
- Behavioral
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Urbana, Illinois
- Conditions
- KRAS Altered Advanced or Metastatic Solid Tumors
- Interventions
- AMG 410, Pembrolizumab, Panitumumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 434 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • Atlanta, Georgia + 7 more
- Conditions
- Obesity and Obesity-related Medical Conditions
- Interventions
- MET233 and MET097, Placebo, MET097
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Carcinoma, Midline
- Interventions
- GSK525762
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more
- Conditions
- Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma
- Interventions
- Treatment with CD200AR-L
- Drug
- Lead sponsor
- OX2 Therapeutics
- Industry
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
- Interventions
- Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI), Specimen Collection, Optional Lumbar puncture
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 12 Months to 25 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Cervical Insufficiency
- Interventions
- Azithromycin Prophylaxis, Azithromycin Placebo, Cefazolin, Progesterone
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Oak Lawn, Illinois • Park Ridge, Illinois
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- YJ001 for Spray Use, Placebo of YJ001 for Spray Use
- Drug
- Lead sponsor
- Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Fredericksburg, Texas
- Conditions
- Healthy
- Interventions
- TC-5214, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Pegasys, RO5024048, danoprevir, ritonavir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 19
- States / cities
- La Jolla, California • Long Beach, California • Sacramento, California + 15 more
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- IPI-145, Fludarabine, Cyclophosphamide, Rituximab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Brain Tumor
- Interventions
- Letrozole Oral Tablet, Temozolomide
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae
- Interventions
- Zopapogene imadenovec (Zopa)
- Drug
- Lead sponsor
- Precigen, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Bethesda, Maryland • Cincinnati, Ohio
- Conditions
- Crohns Disease
- Interventions
- PDA001, Vehicle Controlled Placebo
- Biological · Drug
- Lead sponsor
- Celularity Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Denver, Colorado • Gainesville, Florida + 9 more
- Conditions
- Urothelial Carcinoma
- Interventions
- Erdafitinib, Cetrelimab, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 12
- States / cities
- Aurora, Colorado • Louisville, Kentucky • Rockville, Maryland + 9 more
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- IV pantoprazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 1 Year to 16 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- Dallas, Texas • Salt Lake City, Utah